Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Adams Respiratory Therapeutics, Inc. (ARXT)
|
Add to portfolio |
|
|
|
| Price: |
$43.15
| | Metrics |
| OS: |
36.0
|
M
| |
4
|
% ROE
|
| Market cap: |
$1.55
|
B
| |
29
|
% ROIC
|
|
Net cash:
|
$66.5
|
M
| |
$1.85
|
per share
|
|
EV:
|
$1.49
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$75.7
|
M
| |
19.6
|
x EV/EBITDA
|
|
EBIT
|
$71.1
|
M
| |
20.9
|
x EV/EBIT
|
| EPS |
($848.49)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Jun-30-07 | Jun-30-06 | Jun-30-05 | Jun-30-04 | Jun-30-03 | Jun-30-02 |
| Revenues | 331.6 | 239.1 | 160.2 | 61.3 | 14.0 | 13.8 |
| Revenue growth | 38.7% | 49.2% | 161.4% | 336.6% | 2.1% | |
| Cost of goods sold | 95.8 | 49.4 | 31.1 | 11.9 | 5.3 | 4.0 |
| Gross profit | 235.8 | 189.7 | 129.1 | 49.4 | 8.8 | 9.7 |
| Gross margin | 71.1% | 79.4% | 80.6% | 80.5% | 62.6% | 70.7% |
| Selling, general and administrative | 162.9 | 99.0 | 78.0 | 23.3 | 23.3 | 18.0 |
| Research and development | 23.9 | 18.9 | 7.4 | 3.2 | 4.5 | 7.4 |
| EBIT | 50.3 | 76.2 | 44.4 | 19.7 | -26.3 | -15.7 |
| EBIT margin | 15.2% | 31.8% | 27.7% | 32.1% | -187.1% | -113.8% |
| Pre-tax income | 47.6 | 76.2 | 44.4 | 19.7 | -22.6 | -15.5 |
| Income taxes | 17.0 | 29.8 | 17.4 | -16.1 | 0.0 | 0.0 |
| Tax rate | 35.8% | 39.1% | 39.2% | | 0.0% | 0.0% |
| Net income | 0.0 | 0.0 | -0.2 | 0.0 | -22.6 | -15.5 |
| Net margin | 0.0% | 0.0% | -0.1% | 0.0% | -161.3% | -112.5% |
| |
| Diluted EPS | $0.82 | $1.28 | ($32.97) | $0.90 | ($7,307.30) | ($5.01) |
| Shares outstanding (diluted) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|